Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • TG Therapeutics...

    TG Therapeutics leukemia drug clears key study, shares pop

    Written by supriya kashyap kashyap Published On 2017-03-07T10:56:30+05:30  |  Updated On 7 March 2017 10:56 AM IST
    TG Therapeutics leukemia drug clears key study, shares pop

    TG Therapeutics Inc said a combination of its experimental cancer drug, ublituximab, and approved treatment Imbruvica was found to be more effective in high-risk leukemia patients, compared with Imbruvica as a standalone therapy.


    TG's shares more than doubled in morning trading on Monday.


    The late-stage study involved adult patients with high-risk chronic lymphocytic leukemia (CLL) who have undergone at least one prior therapy.


    The trial was designed to evaluate whether adding ublituximab would induce a statistically significant improvement in overall response rate by at least 20 percent between the two groups of patients.


    The absolute difference between the two groups was about 30 percent, the company said on Monday.


    TG said it would meet with the U.S. Food and Drug Administration to discuss accelerated approval.


    A separate late-stage study testing ublituximab to treat multiple sclerosis is expected to begin later this year, pending the outcome of a mid-stage trial.


    Ublituximab is also being evaluated in combination with another TG experimental drug, TGR-1202, for use in CLL and diffuse large B-cell lymphoma.


    In 2015, AbbVie Inc forked out $21 billion for Pharmacyclics, giving it joint ownership of the blockbuster leukemia treatment, Imbruvica, with Johnson & Johnson.


    Imbruvica, which is also approved to treat mantle cell lymphoma and a type of non-Hodgkin's lymphoma, generated $1.83 billion in sales for AbbVie last year.


    The American Cancer Society has estimated that about 20,110 cases of CLL will be diagnosed in the United States in 2017, and the disease could claim 4,660 lives.


    New York-based TG's shares were up about 87 percent at $10 in morning trading.

    AbbViecancer drugChronic lymphocytic leukemiaImbruvicaJohnson and Johnsonleukemia drugTG Therapeuticsublituximab
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok